retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial Eli Lilly's shows promising weight loss results in 3 Triple Agonism Based Therapies for

PurpleLab, using its healthcare claims database and HealthNexus analytics platform, analyzed medical and pharmacy claims for 12.2M people taking GLP-1 medications from January 2019 May 2024

Once you stop the medication, your gastric emptying rate returns to normal

However, changes in the reproductive axis and ovarian morphology were not consistent across all endpoints, and gastrointestinal adverse events were common (96, 97)

[DOI] [PubMed] [Google Scholar] 129.GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives

Giacosa A, Guido D, Grassi M, et al

(30, 31) However, they also highlight potential cardiovascular and renal risks, emphasizing the need for careful perioperative monitoring and patient selection